A practical reference on IGF-1: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-20. Anything still debated is marked as such rather than presented as settled.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
The use of C–H functionalization in the synthesis of lithospheric acid exemplifies the site- and stereoselective capabilities of using MPAA ligands in these reactions. As the penultimate step, the intermolecular C–H olefination introduces almost double the complexity into the compound enabling the highly convergent synthesis.
In her resignation letter to Starmer she said, "The sleaze, nepotism and apparent avarice are off the scale. I am so ashamed of what you and your inner circle have done to tarnish and humiliate our once proud party". Charles III marks the 25th anniversary of the establishment of the Scottish Parliament at an event in Edinburgh. Rachael Hamilton is appointed deputy leader of the Scottish Conservatives. 2024 Ulster Unionist Party leadership election: Mike Nesbitt is confirmed as the UUP's new leader at the party's annual conference. Sinn Féin president Mary Lou McDonald tells her party's annual conference in the Republic of Ireland that the next Irish government will include a Minister for Reunification if Sinn Féin are part of the administration. 29 September – Cabinet Office minister Pat McFadden confirms that ministers will be required to declare hospitality linked to their government posts following weeks of headlines about Starmer and other senior ministers receiving gifts from major Labour donor Lord Alli. The Conservative Party Conference begins in Birmingham, with the first day dominated by a row over comments made by leadership candidate Kemi Badenoch, who said maternity pay had "gone too far". Badenoch says her comments have been "misrepresented" and refer to the broader issue of cutting red tape for businesses. Sunak makes his farewell speech as Conservative Party leader, urging the party to unite behind his successor.
The episode is now considered to be a serious breach of medical ethics and of the Hippocratic Oath. The government covered up most of these actions until 1993, when President Bill Clinton ordered a change of policy and federal agencies then made available relevant records. The resulting investigation was undertaken by the president's Advisory Committee on Human Radiation Experiments, and it uncovered much of the material about plutonium research on humans. The committee issued a controversial 1995 report which said that "wrongs were committed" but it did not condemn those who perpetrated them.
Sources: en.wikipedia.org
==== Non-arising ==== Some Mahāyāna sūtras contain statements which speak of the "unarisen" or "unproduced" (anutpāda) nature of dharmas. According to Edward Conze, in the Prajñāpāramitā sutras, the ontological status of dharmas can be described as having never been produced (anutpāda), as never been brought forth (anabhinirvritti), as well as unborn (ajata). This is illustrated through various similies such as a dream, an illusion and a mirage. Conze also states that the "patient acceptance of the non-arising of dharmas" (anutpattika-dharmakshanti) is "one of the most distinctive virtues of the Mahāyānistic saint."
==== United Kingdom ==== All drugs in the 2C family are Class A under the Misuse of Drugs Act which means they are illegal to produce, supply or possess. Possession carries a maximum sentence of seven years imprisonment while supply is punishable by life imprisonment and an unlimited fine.
The ionizing radiation emitted by radium bromide excites nitrogen molecules in the air, making it glow. The alpha particles emitted by radium quickly gain two electrons to become neutral helium, which builds up inside and weakens radium bromide crystals. This effect sometimes causes the crystals to break or even explode. Radium nitrate (Ra(NO3)2) is a white compound that can be made by dissolving radium carbonate in nitric acid. As the concentration of nitric acid increases, the solubility of radium nitrate decreases, an important property for the chemical purification of radium. Radium forms much the same insoluble salts as its lighter congener barium: it forms the insoluble sulfate (RaSO4, the most insoluble known sulfate), chromate (RaCrO4), carbonate (RaCO3), iodate (Ra(IO3)2), tetrafluoroberyllate (RaBeF4), and nitrate (Ra(NO3)2). With the exception of the carbonate, all of these are less soluble in water than the corresponding barium salts, but they are all isostructural to their barium counterparts. Additionally, radium phosphate, oxalate, and sulfite are probably also insoluble, as they coprecipitate with the corresponding insoluble barium salts. The great insolubility of radium sulfate (at 20 °C, only 2.1 mg will dissolve in 1 kg of water) means that it is one of the less biologically dangerous radium compounds. The large ionic radius of Ra2+ (148 pm) results in weak ability to form coordination complexes and poor extraction of radium from aqueous solutions when not at high pH.
Sources: en.wikipedia.org
Unlike M1 macrophages, M2 macrophages secrete an anti-inflammatory response via the addition of Interleukin-4 or Interleukin-13. They also play a role in wound healing and are needed for revascularization and reepithelialization. M2 macrophages are divided into four major types based on their roles: M2a, M2b, M2c, and M2d. How M2 phenotypes are determined is still up for discussion but studies have shown that their environment allows them to adjust to whichever phenotype is most appropriate to efficiently heal the wound. M2 macrophages are needed for vascular stability. They produce vascular endothelial growth factor-A and TGF-β1. There is a phenotype shift from M1 to M2 macrophages in acute wounds, however this shift is impaired for chronic wounds. This dysregulation results in insufficient M2 macrophages and its corresponding growth factors that aid in wound repair. With a lack of these growth factors/anti-inflammatory cytokines and an overabundance of pro-inflammatory cytokines from M1 macrophages chronic wounds are unable to heal in a timely manner. Normally, after neutrophils eat debris/pathogens they perform apoptosis and are removed. At this point, inflammation is not needed and M1 undergoes a switch to M2 (anti-inflammatory). However, dysregulation occurs as the M1 macrophages are unable/do not phagocytose neutrophils that have undergone apoptosis leading to increased macrophage migration and inflammation. Both M1 and M2 macrophages play a role in promotion of atherosclerosis. M1 macrophages promote atherosclerosis by inflammation.
== Signs and symptoms == Often, food illnesses are not attributed to A. parasiticus because it is mistaken for A. flavus. Serious symptoms of aflatoxin exposure by either ingestion or inhalation of spores, or through direct skin contact, can occur amongst humans and animals. Signs and symptoms of exposure in humans may include delayed development and stunted growth among children, while adults may experience teratogenic effects, lung damage, ulcers, skin irritation, fever, and acute liver disease, which can later lead to liver carcinoma and death.
==== Territorial Grand Orient ==== In the pursuit of an independent and Cuban authority, on May 14, 1821, the Grand Consistory developed the Grande Oriente Territorial Espanol-Americano-Rita Escoces de Francos-masones antiguos y aceptados (English: Territorial Grand Orient of the Spanish-American-Scottish Rite of Ancient and Accepted Freemasons), which was established in Havana. This Grand Orient was then further divided into the Symbolic Grand Orient and the Grand Consistory. Many members of this Grand Orient were officers of the Spanish Army and the Spanish Navy. Their ambitions were evident in the fact that they claimed to hold jurisdiction over Spanish Puerto Rico, New Spain, Mexico, The Floridas, Santo Domingo, and Haiti. On their roster of Lodges, they indeed held authority over a Lodge in Tabasco called Los Amigos Filantropicos (English: Philanthropic Friends).
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.